Navigation Links
MD Anderson announces immunotherapy collaboration with GSK
Date:4/8/2014

HOUSTON The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

The collaboration completes an ambitious plan to partner with leading pharmaceutical companies to more rapidly develop cancer immunotherapies as part of MD Anderson's Moon Shots Program. Through this venture, GSK and MD Anderson will work together to identify new therapeutic approaches, evaluate patient responses in clinical trials and use those insights to develop immunotherapy drugs.

"With this agreement, we've now completed our fourth and final major collaboration with large companies who share our commitment to deliver on the promise of immunotherapy, using the resources of our immunotherapy platform," said Ferran Prat, Ph.D., J.D., and vice president of MD Anderson Strategic Industry Ventures. "We're also committed to help leading start-ups establish a foothold in this exciting field, but collaborating with this select group of highly committed companies will help bring new therapies to patients faster."

"This collaboration brings together MD Anderson's basic science capabilities with GSK's drug discovery and development expertise, and our growing immuno-oncology portfolio," said Axel Hoos, M.D., Ph.D., VP Oncology R&D, who leads GSK's immuno-oncology programs and has previous experience working with MD Anderson in this field. "The alliance will build on the strengths of both organizations to innovate in translational research, which will enhance drug development programs in this fast-growing area." Hoos developed the first immune checkpoint modulatory antibody (anti-CTLA-4) in a previous partnership with MD Anderson's Jim Allison, Ph.D.

MD Anderson recognized the potential of immune-based therapies by creating one of the platforms that supports its Moon Shoots Program, the institution's 10-year commitment to more rapidly develop therapies and other interventions to significantly reduce cancer deaths.

"We welcome the opportunity to work closely with GSK to build upon the early successes of immunotherapy by extending this approach to many types of cancer and exploring ways to improve treatment effectiveness," said Jim Allison, Ph.D., MD Anderson chair of Immunology and executive director of the immunotherapy platform.

Allison's basic science research on T-cell biology led to an entirely new method of treating cancer called immune checkpoint blockade, which blocks receptors on the surface of T-cells that stop an immune attack. He created an antibody to the checkpoint CTLA-4, which became the first drug of any type approved for use in late-stage melanoma. Additional checkpoints have since been identified and new drugs to treat them are under development.

"Unlike other cancer drugs that treat certain cancer types or specific molecular targets on a tumor, immune checkpoint blockade treats the immune system, freeing it to attack any type of cancer," Allison said.

Other immunotherapy platform leaders include co-director Patrick Hwu, M.D., chair of Melanoma Medical Oncology, and scientific director Padmanee Sharma, M.D., Ph.D., associate professor of Genitourinary Medical Oncology.

Hwu is one of the leading tumor immunologists in the country, whose work in the development of novel vaccines and T-cell therapies explores new ways of treating cancer. He and Allison will work closely with GSK scientists to quickly bridge the gap between discoveries in the lab and drugs that will benefit patients.


'/>"/>

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. MD Anderson honors 2 champions for women in medicine and research
2. MD Anderson, MedImmune join forces to advance cancer immunotherapy
3. MD Anderson researcher uncovers some of the ancient mysteries of leprosy
4. Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
5. MD Anderson guides intelligent redesign of cancer care delivery model
6. MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology rese
7. 4 from UT MD Anderson named Fellows in AAAS
8. Super Bowl Champion OJ Anderson Treated By Pro Player Health Alliance For Sleep Apnea With A Dental Device
9. Sleep Apnea Treatment Becoming More Popular in New York After Long Island Dental Sleep Medicine Begins Treatment on OJ Anderson, Giants Super Bowl Champion
10. Colleen’s Dream Foundation Gifts $10,000 to The University of Texas MD Anderson Cancer Center to Support Ovarian Cancer Research
11. MD Anderson educators win AEIRS/Elsevier Innovator of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... , ... CURE Media Group, the nation’s leading digital and print media enterprise ... Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael J. ... Group is honored to team up with Upstage Lung Cancer in order to make ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc . ... um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast during ... at Wuhan Union Hospital ...
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
Breaking Medicine Technology: